During the weekend, two of the most advanced laboratories in the search for a coronavirus vaccine made an interesting announcement. They are of course Sanofi and GSK who are collaborating in the development of such a vaccine and who announced a cost of less than ten euros per dose for it. This is in any case what the president of Sanofi France, Olivier Bogillot, said during an interview given on France Inter on Saturday.
Olivier Bogillot said during this radio interview: "French and European patients will get Sanofi's vaccine at the same time as American patients. We signed during the summer with the Americans, the same week with the Europeans and with the British". According to his words, the United States will benefit from 100 million doses and the Europeans from 300 million doses. As for Great Britain, 60 million doses will be reserved for it.
The vaccine that will be sold in the European Union will be manufactured in France and more precisely in Vitry Sur Seine in the Val de Marne, as the director of Sanofi France reminded us. The latter also greeted his association with the British laboratory GSK within the framework of this operation by indicating: "It is not common to associate with a competitor but it is rather healthy in this war against Covid". It also states that millions of doses will also be supplied to developing countries through the Sepi structure and at quite exceptional tariff conditions.
The Sanofi group also indicated that it was in the process of measuring all the production costs of this vaccine that it will incur and thus announced that the dose of this vaccine will be marketed at a price of less than €10. He also welcomed the sharing of risks with the States, which enabled him to have the lowest possible prices in this particular context of health emergency.
It should be noted, however, that the competitor AstraZeneca had previously announced that it was also developing a vaccine that could be marketed at a price of €2.50. But Olivier Bogillot also came back on the announcement of this other laboratory in the race against Covid-19 and explains in particular this price difference by the fact that Sanofi currently uses all its resources internally as well as its own researchers and its own factories in order to develop and produce this vaccine. For its part, AstraZeneca has outsourced a large part of its production, which allows it to charge a lower price.
Of course, it remains to follow the evolution of the different test phases of this candidate vaccine in the weeks and months to come.